Aromatase inhibitor tablets for endocrine-responsive cancers in oncology protocols. Utilized in cancer treatment centers, hospitals, and specialized clinics; manufactured by pharmaceutical companies and procured via oncology supply chains for oncologists and healthcare facilities.